AMED vs. ADUS, AHCO, OPCH, GKOS, ARWR, IART, PDCO, CYTK, DNA, and ITGR
Should you be buying Amedisys stock or one of its competitors? The main competitors of Amedisys include Addus HomeCare (ADUS), AdaptHealth (AHCO), Option Care Health (OPCH), Glaukos (GKOS), Arrowhead Pharmaceuticals (ARWR), Integra LifeSciences (IART), Patterson Companies (PDCO), Cytokinetics (CYTK), Ginkgo Bioworks (DNA), and Integer (ITGR). These companies are all part of the "medical" sector.
Addus HomeCare (NASDAQ:ADUS) and Amedisys (NASDAQ:AMED) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, community ranking, media sentiment, risk, profitability, analyst recommendations and dividends.
Amedisys received 187 more outperform votes than Addus HomeCare when rated by MarketBeat users. However, 66.90% of users gave Addus HomeCare an outperform vote while only 58.19% of users gave Amedisys an outperform vote.
95.3% of Addus HomeCare shares are held by institutional investors. Comparatively, 95.7% of Amedisys shares are held by institutional investors. 4.4% of Addus HomeCare shares are held by insiders. Comparatively, 1.8% of Amedisys shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Addus HomeCare presently has a consensus target price of $107.50, indicating a potential upside of 20.57%. Amedisys has a consensus target price of $103.55, indicating a potential upside of 10.14%. Given Amedisys' stronger consensus rating and higher possible upside, analysts clearly believe Addus HomeCare is more favorable than Amedisys.
Amedisys has higher revenue and earnings than Addus HomeCare. Addus HomeCare is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.
Addus HomeCare has a net margin of 5.61% compared to Addus HomeCare's net margin of 0.12%. Addus HomeCare's return on equity of 13.45% beat Amedisys' return on equity.
Addus HomeCare has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Amedisys has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500.
In the previous week, Amedisys had 3 more articles in the media than Addus HomeCare. MarketBeat recorded 5 mentions for Amedisys and 2 mentions for Addus HomeCare. Amedisys' average media sentiment score of 1.32 beat Addus HomeCare's score of 0.37 indicating that Addus HomeCare is being referred to more favorably in the media.
Summary
Addus HomeCare and Amedisys tied by winning 9 of the 18 factors compared between the two stocks.
Get Amedisys News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Amedisys Competitors List
Related Companies and Tools